BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

Background Effectiveness data on novel oral anticoagulants (NOACs) versus warfarin for
stroke prevention in non-valvular atrial fibrillation (NVAF) by prior warfarin use are limited …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are dose-
reduced in elderly and patients with impaired renal function. Only reduced dose dabigatran …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

We performed a meta-analysis of data on the effectiveness and safety of apixaban
compared with other oral anticoagulants (warfarin or rivaroxaban or dabigatran or …

Aims Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and
presents a potential issue for the effective management of NVAF. This study compared the …

Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …